Assembly Biosciences(US:ASMB) Globenewswireยท2025-08-06 20:05Core Insights - Assembly Biosciences, Inc. is advancing its clinical programs with significant data expected in 2025 for four development candidates targeting serious viral diseases [2][3] - The company reported positive topline data for ABI-4334 in chronic hepatitis B virus (HBV) and interim data for ABI-6250 in healthy volunteers [1][2] - ABI-5366 and ABI-1179 are on track for proof-of-concept Phase 1b data by fall 2025 for recurrent genital herpes [1][2] Financial Performance - As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $75.0 million, down from $91.0 million as of March 31, 2025 [11] - Revenue from collaborative research with Gilead was $9.6 million for the second quarter of 2025, compared to $8.5 million in the same period of 2024 [11] - Research and development expenses were $16.1 million for the second quarter of 2025, slightly down from $16.3 million in the same period of 2024 [11] Clinical Development Updates - ABI-1179 has entered the Phase 1b portion of its trial, with positive topline results for ABI-4334 indicating strong antiviral activity in chronic HBV [6] - ABI-6250's interim data showed pharmacokinetics supportive of a once-daily oral dosing profile and biomarker data indicating target engagement [6] - Upcoming presentations and data releases are scheduled for various international conferences, highlighting the company's ongoing research efforts [6][4] Anticipated Milestones - Key proof-of-concept Phase 1b data for ABI-5366 and ABI-1179 is expected no later than fall 2025 [6] - An abstract for ABI-6250 has been accepted for oral presentation at the International HBV Meeting in September 2025 [6] Company Overview - Assembly Biosciences is focused on developing innovative small-molecule therapeutics for serious viral diseases, including herpesvirus, HBV, and hepatitis delta virus (HDV) [8] - The company is led by a team experienced in virologic drug development, aiming to improve patient outcomes [8]